Zevra Therapeutics, Inc. Sustainability Profile
Zevra Therapeutics, Inc., headquartered in the United States, is a pioneering biopharmaceutical company focused on developing innovative therapies for rare diseases and unmet medical needs. Founded in 2020, Zevra has quickly established itself in the biotechnology industry, particularly in the areas of neurology and rare genetic disorders. The company’s core offerings include unique therapeutic solutions that leverage advanced scientific research and technology, setting them apart in a competitive market. Zevra's commitment to addressing complex health challenges has led to significant milestones, including the advancement of its lead product candidates through various stages of clinical development. With a strong emphasis on patient-centric approaches, Zevra Therapeutics is poised to make a meaningful impact in the lives of those affected by rare conditions.
DitchCarbon Score
How does Zevra Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zevra Therapeutics, Inc.'s score of 23 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zevra Therapeutics, Inc.'s reported carbon emissions
Zevra Therapeutics, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Zevra Therapeutics may still be in the early stages of developing its climate commitments or reporting frameworks. As the biopharmaceutical industry increasingly prioritises sustainability, it is essential for companies like Zevra Therapeutics to establish clear emissions reduction targets and strategies. This would not only align with global climate initiatives but also enhance their corporate responsibility profile. Without specific emissions data or commitments, it remains unclear how Zevra Therapeutics plans to address its environmental impact in the future.
How Carbon Intensive is Zevra Therapeutics, Inc.'s Industry?
How Carbon Intensive is Zevra Therapeutics, Inc.'s Location?
Zevra Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Zevra Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
